Top Story

Patient-centered medical home program decreased hospital use, lowered care costs

August 22, 2014

In the 3 years since its introduction, CareFirst Blue Cross Blue Shield’s Patient-Centered Medical Home model has resulted in reduced hospital utilization, lower health care costs to members and increased reimbursements for participating panels, Blue Cross Blue Shield announced in a press release.

The company provided 3-year results from their Patient-Centered Medical Home program, which was implemented in 2011. Over 80% of all primary care providers located in the CareFirst service area, which includes parts of Northern Virginia, the District of Columbia and Maryland, are participants.

figure In the Journals

Campaign focuses on reducing HBV in Chinese city

August 22, 2014
The implementation phase of a cooperative that focuses on public awareness of hepatitis B virus in a city in China has laid vital groundwork, according to recent study…
figure In the Journals

Questionnaire accurately measured QOL among pediatric liver transplant recipients

August 22, 2014
A novel Pediatric Liver Transplantation Quality of Life questionnaire was valid and accurate in measuring quality of life among adolescent liver transplant recipients…
figure In the Journals

Infliximab caused DILI most frequently among TNF-a antagonists

August 22, 2014
Among tumor necrosis factor-alpha antagonists, infliximab was most commonly associated with drug-induced liver injury, according to recent study data.Einar S
More News Headlines »
CME

HCV Consults: Volume 1, Number 2

This activity is supported by educational grants from AbbVie and Genentech.

5/1/2014
Approved interferon-free therapy has already become entrenched among clinicians for patients with HCV genotypes 2 and…
More »
Meeting News Coverage Video
figure

Tenofovir/entecavir recommended for HBV patients with malignancy

May 16, 2014
CHICAGO — Spilios Manolakopoulos, MD, of the internal medicine and hepatology departments at…
More »
CME

HCV Consults: Volume 1, Number 1

This activity is supported by educational grants from AbbVie and Genentech.

4/1/2014
Physicians seldom experience a paradigm shift in disease management as great as that transpiring in HCV therapy. With…
More »